Similarly to the present study, the beneficial effects exerted by this compound in chronic inflammatory diseases, such as multiple sclerosis and inflammatory bowel disease, were largely explained by its interaction with S1P1 and not with S1P5: S1P1 is therefore considered its primary therapeutic target. This evidence concerns the gene S1PR5 and inflammatory bowel disease.